These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35289700)

  • 1. How China controls the Covid-19 epidemic through public health expenditure and policy?
    Jin H; Li B; Jakovljevic M
    J Med Econ; 2022; 25(1):437-449. PubMed ID: 35289700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How the Chinese Government Has Done with Public Health from the Perspective of the Evaluation and Comparison about Public-Health Expenditure.
    Jin H; Qian X
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33322428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Health Crises In Comparison: China's Epidemic Response Policies From SARS To COVID-19.
    Li M
    Glob Public Health; 2021; 16(8-9):1223-1236. PubMed ID: 33891518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. China's model to combat the COVID-19 epidemic: a public health emergency governance approach.
    Ning Y; Ren R; Nkengurutse G
    Glob Health Res Policy; 2020; 5():34. PubMed ID: 32685691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining and quantitative evaluation of COVID-19 policy tools in China.
    Liu J; Li N; Cheng L
    PLoS One; 2023; 18(4):e0284143. PubMed ID: 37027438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. China's Public Health Policies in Response to COVID-19: From an "Authoritarian" Perspective.
    Gao J; Zhang P
    Front Public Health; 2021; 9():756677. PubMed ID: 34976920
    [No Abstract]   [Full Text] [Related]  

  • 7. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
    Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
    Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. China's "dynamic clearing" epidemic prevention policy: Achievements, challenges, and prospects.
    Wang Q; Huang L
    Front Public Health; 2022; 10():978944. PubMed ID: 36187631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the patterns of China's policies against COVID-19: A bibliometric study.
    Wu J; Wang K; He C; Huang X; Dong K
    Inf Process Manag; 2021 Jul; 58(4):102562. PubMed ID: 33678941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflection and Foresight on Personal Information Protection and Optimization in Public Health Emergencies in China-From the Perspective of Personal Information Collection during the Period of China's Dynamic-Zero COVID-19 Prevention and Control Policy.
    Wang H
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whether Social Participation Can Affect the Central Government Public Policy Response to the COVID-19 in China.
    Fu L; Sun H; Xu K
    Front Public Health; 2022; 10():842373. PubMed ID: 35570925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public Engagement and Government Responsiveness in the Communications About COVID-19 During the Early Epidemic Stage in China: Infodemiology Study on Social Media Data.
    Liao Q; Yuan J; Dong M; Yang L; Fielding R; Lam WWT
    J Med Internet Res; 2020 May; 22(5):e18796. PubMed ID: 32412414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the Experience of Public Health System Construction in China's COVID-19 Prevention.
    Zhang P
    Front Public Health; 2021; 9():610824. PubMed ID: 33981659
    [No Abstract]   [Full Text] [Related]  

  • 14. Three phases of COVID-19: theoretical thinking on epidemic prevention and control.
    Lu W; Huang Y; Gao C; Cai Y; Yang L
    Ann Palliat Med; 2021 Jul; 10(7):8271-8275. PubMed ID: 34353108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research on the Dynamic Feedback Mechanism of Fiscal Policy Regulation Under COVID-19: Evidence From China.
    Wang S; Gao H; Zhou B
    Front Public Health; 2022; 10():931135. PubMed ID: 35865240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Government and Capital Market's Response to Normalized Epidemic Prevention and Control Based on the Development of Smart Health Care.
    Wang X; Wang X; Li J; Song R
    J Healthc Eng; 2022; 2022():8122322. PubMed ID: 36451762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Matters More in Fighting COVID-19-Government Policy or Community Participation?
    Qian Y; Huang J; Zhao L; Cheong IH; Cao S; Xiong L; Zhu Q
    Front Public Health; 2022; 10():927553. PubMed ID: 35903372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. China's Fight Against COVID-19: What We Have Done and What We Should Do Next?
    Cheng S; Zhao Y; Kaminga AC; Zhang X; Xu H
    Front Public Health; 2022; 10():548056. PubMed ID: 35844877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
    Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
    Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing the Characteristics of Policies and Political Institutions for the Prevention and Control Governance of the COVID-19 Pandemic: Evidence from China.
    Dong M; Zhou C; Zhang Z
    Int J Environ Res Public Health; 2022 Sep; 19(17):. PubMed ID: 36078703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.